Alveolar Bone Loss
Conditions
Brief summary
The goal of this clinical trial is to test in height increment of alveolar bone and safety evaluation index. The main question it aims to answer are: • The safety and effectiveness of magnesium calcium silicate three-dimensional alveolar bone repair unit in the repair of periodontal bone defects Participants will be treated through Guided Bone Regeneration operation with calcium magnesium silicate three-dimensional alveolar bone repair unit.
Interventions
DEVICEGBR with CS@Mg
The patient was treated by GBR with magnesium calcium silicate scaffold for alveolar bone defect.
Sponsors
Second Affiliated Hospital, School of Medicine, Zhejiang University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Device: GBR with CS@Mg The patient was treated by GBR with magnesium calcium silicate scaffold for alveolar bone defect.
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Age 18-65 years old, healthy; * Good oral hygiene, do not smoke; * There is bone defect at the tooth extraction site, and it is planned to carry out implant repair after tooth extraction; * There is at least one healthy adjacent tooth in the mesial and distal surface of the tooth extraction site; * The residual height from the bottom of the extraction socket to the crest of the alveolar ridge is ≥ 3 mm, with at least one bone wall; * Can understand the purpose of the trial * Be willing to cooperate with surgical treatment and follow-up, voluntarily participate in the trial * Sign the informed consent form.
Exclusion criteria
* The affected tooth is in the acute inflammatory stage; * Those who have bad habits such as smoking and drinking； * Subjects who cause artifacts in oral imaging examination, such as the extraction site and its adjacent teeth are metal Dentures, porcelain teeth; * Patients are allergic to ceramic implants; * Those who have participated in other clinical trials in the past 3 months; * The investigator estimated that the compliance was poor, or there were other factors that were not suitable for the test; * Patients with a history of diabetes or abnormal blood glucose detection (fasting blood glucose ≥ 7mmol/L); * Abnormal liver and kidney function (AST, ALT, creatinine ≥ 1.5 times ULN); * Patients with serious endocrine and metabolic diseases; * Have a history of tertiary hypertension; * Have a history of osteoporosis; * Those who are not suitable for surgery due to the history of malignant tumor or other serious diseases; * People with a history of autoimmune diseases; * Pregnant or lactating women; * Mental disorders without autonomous behavior ability; * Patients who are using steroids that interfere with calcium metabolism within 3 months before the signing of informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Horizontal bone width | 24 weeks after operation | The width of buccal lingual alveolar ridge was measured 1 mm below the crest of alveolar ridge. |
| Evaluation of wound healing | 2 weeks after operation | The wound healing evaluation scale was modified according to the indicators described by Lobene et al (1986) and will be used to evaluate the wound healing after surgery. The gingival tissue in the material implantation area was evaluated. |
Countries
China
Contacts
Primary ContactLili Chen, Prof.
Outcome results
None listed